Bat virome

Paragon Genomics Highlights Year of Rapid Growth Fueled by Broad Acceptance of Its CleanPlex® SARS-CoV-2 Research and Surveillance Products

Retrieved on: 
Tuesday, April 27, 2021

"\nParagon Genomics\' CleanPlex SARS-CoV-2 technology has powered variant detection and tracking since the virus first appeared.

Key Points: 
  • "\nParagon Genomics\' CleanPlex SARS-CoV-2 technology has powered variant detection and tracking since the virus first appeared.
  • In March 2020, the company launched the CleanPlex SARS-CoV-2 Panel whole genome SARS-CoV-2 sequencing on Illumina and MGI Tech sequencing platforms.
  • "\nParagon Genomics CleanPlex SARS-CoV-2 Emerging Variant Panel Add-On is designed to be used with existing CleanPlex SARS-CoV-2 products to maintain uniform genomic coverage for variant calling and identification.
  • The company designs and manufactures high performance and ultra-multiplexed amplicon NGS library preparation products for analyzing difficult, clinically relevant samples.

SpeeDx Receives CE-IVD Mark for PlexPCR® SARS-CoV-2

Retrieved on: 
Monday, April 26, 2021

View the full release here: https://www.businesswire.com/news/home/20210426005269/en/\nThe PlexPCR\xc2\xae SARS-CoV-2 assay targets two highly conserved regions of the SARS-CoV-2 genome.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210426005269/en/\nThe PlexPCR\xc2\xae SARS-CoV-2 assay targets two highly conserved regions of the SARS-CoV-2 genome.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
  • SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers.
  • SpeeDx ResistancePlus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.\nFor more information about SpeeDx please see: http://plexpcr.com\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005269/en/\n'

Infinity BiologiX (IBX) Awarded CDC Contract to Sequence Variants of COVID-19 Virus and Assist in Global Public Health Response

Retrieved on: 
Tuesday, April 13, 2021

View the full release here: https://www.businesswire.com/news/home/20210413005510/en/\nIBX NextSeq used for COVIDSeq strain determination.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210413005510/en/\nIBX NextSeq used for COVIDSeq strain determination.
  • (Photo: Business Wire)\nIBX will sequence the viral genomes of random, de-identified samples in the US that test positive in the course of providing molecular diagnostic testing for SARS-CoV-2 for providers and patients.
  • IBX will provide the CDC with completed whole viral sequences in order to aid the CDC in its large-scale longitudinal genomic survey of the virus.
  • IBX provides global sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas.

Metrex Surface Disinfectant Portfolio Secures EPA Approval for Use Against SARS-CoV-2 Virus

Retrieved on: 
Monday, April 5, 2021

The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex , as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Key Points: 
  • The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex , as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.
  • View the full release here: https://www.businesswire.com/news/home/20210405005058/en/
    The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex, as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.
  • The below Metrex surface disinfection products are effective against SARS-CoV-2, helping to give front-line workers peace of mind that our products are protecting their patients and themselves.
  • The following Metrex products have been approved by the EPA for efficacy against SARS-CoV-2 and are on the EPA list N for use against SARS-CoV-2:

EUROIMMUN Launches SARS-CoV-2 NeutraLISA Assay to Determine the Neutralizing Capacity of Anti-SARS-CoV-2 Antibodies

Retrieved on: 
Thursday, April 1, 2021

EUROIMMUN , a PerkinElmer, Inc. Company, today announced the launch of the SARS-CoV-2 NeutraLISA assay, a surrogate neutralization test intended for the detection of neutralizing antibodies against SARS-CoV-2, the pathogen causing COVID-19.

Key Points: 
  • EUROIMMUN , a PerkinElmer, Inc. Company, today announced the launch of the SARS-CoV-2 NeutraLISA assay, a surrogate neutralization test intended for the detection of neutralizing antibodies against SARS-CoV-2, the pathogen causing COVID-19.
  • However, if the RBD is blocked by specific antibodies formed during immune response, the virus cannot continue to infect and proliferate within the human body.
  • The EUROIMMUN SARS-CoV-2 NeutraLISA imitates this natural process by determining the inhibitory effect of antibodies capable of hampering the interaction between biochemically produced RBD and ACE2.
  • The SARS-CoV-2 NeutraLISA assay supplements EUROIMMUNs existing CE-marked QuantiVac ELISA and SARS-CoV-2 Interferon-gamma Release Assay which is expected to be available with CE mark soon.

NanoString's GeoMx Digital Spatial Profiler Reveals Insights into COVID-19 in Two New Nature Publications

Retrieved on: 
Wednesday, March 31, 2021

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced that two peer-reviewed publications using the GeoMx Digital Spatial Profiler have been published in Nature and Nature Communications.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced that two peer-reviewed publications using the GeoMx Digital Spatial Profiler have been published in Nature and Nature Communications.
  • These papers describe the use of Digital Spatial Profiling (DSP) technology to investigate SARS-CoV-2 infection and drive diagnostic, prevention, and treatment strategies.
  • The GeoMx DSP was used to profile lung tissue collected on autopsy from patients who had succumbed to COVID-19 infection.
  • The companys GeoMx Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

renegade.bio Teams Up with Umoja Health/BayPLS and Alameda County, California for COVID-19 Vaccine Distribution and Testing in Underserved Bay Area Communities

Retrieved on: 
Wednesday, March 31, 2021

"As a public benefit corporation, renegade.bio is committed to the communities we serve and we are excited to offer both vaccine and SARS-CoV-2 testing in one convenient location," said Craig Rouskey, CEO, renegade.bio.

Key Points: 
  • "As a public benefit corporation, renegade.bio is committed to the communities we serve and we are excited to offer both vaccine and SARS-CoV-2 testing in one convenient location," said Craig Rouskey, CEO, renegade.bio.
  • The Centers for Disease Control and Prevention estimates that African Americans are 1.4 times more likely to contract COVID-19 compared to their Caucasian counterparts.
  • Umoja Health, an initiative of the University of California San Francisco (UCSF) and other community health organizations, have been instrumental in reaching underserved communities.
  • In addition, their work with local governments, the company has run COVID-19 testing programs for the NBA and the San Francisco Giants.

ECDC report examines SARS-CoV-2 transmission risk from vaccinated/previously infected individuals

Retrieved on: 
Tuesday, March 30, 2021

In the Technical Report 'Risk for SARS-CoV-2 transmission from newly infected individuals with documented previous infection or vaccination', published today, ECDC examines the evidence on the extent previous SARS-CoV-2 infection or COVID-19 vaccination prevents onward transmission from infected individuals to susceptible contacts.

Key Points: 
  • In the Technical Report 'Risk for SARS-CoV-2 transmission from newly infected individuals with documented previous infection or vaccination', published today, ECDC examines the evidence on the extent previous SARS-CoV-2 infection or COVID-19 vaccination prevents onward transmission from infected individuals to susceptible contacts.
  • We also welcome the positive early indications that the risk of onward transmission seems to be reduced in those who are vaccinated.
  • Concerning transmission from previously infected individuals, the following key points were concluded:
    No studies directly measured SARS-CoV-2 transmission from reinfected individuals to their contacts.
  • There is also some evidence of lower viral load and shorter duration of shedding in vaccinated individuals as compared to unvaccinated individuals, which could translate into reduced transmission.

AcademicInfluence.com Welcomes Editor Dave Tomar, Expert on Cheating, As He Addresses COVID-19's Impact on the Student Cheating Surge

Retrieved on: 
Monday, March 29, 2021

Sadly, cheating is rampant at all levels of education, and it may have an ally in an unlikely source: SARS-CoV-2, the novel coronavirus.

Key Points: 
  • Sadly, cheating is rampant at all levels of education, and it may have an ally in an unlikely source: SARS-CoV-2, the novel coronavirus.
  • Today, AcademicInfluence.com tackles this challenge of pandemics and cheating with its own triple threat, naming Dave Tomar its new Managing Editor.
  • The article explores student despair as a core driver of cheating at a time when students have never been more vulnerable or at risk.
  • AcademicInfluence.com is a part of the EducationAccess group, a family of sites dedicated to lifelong learning and personal growth.

BioVaxys Expands Intellectual Property Portfolio

Retrieved on: 
Wednesday, March 24, 2021

BioVaxys President and Chief Operating Officer Kenneth Kovan states that "Because of the time and expense associated with developing novel products, BioVaxys places considerable importance on obtaining patent protection for new technologies, uses, and processes.

Key Points: 
  • BioVaxys President and Chief Operating Officer Kenneth Kovan states that "Because of the time and expense associated with developing novel products, BioVaxys places considerable importance on obtaining patent protection for new technologies, uses, and processes.
  • For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trades on the Frankfurt Bourse (FRA: 5LB) and US OTC: LMNGF.